Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) today announced that it will host a conference call and live webcast on Wednesday, December 21, 2011 at 8:30 am EST to communicate its 2012 business outlook, followed by a question and answer session. The company did not provide any further details.
The analysts full-year 2012 consensus is $5.67 earnings per share on $21.8 billion revenue. Their fourth quarter 2011 consensus is $1.57 earnings per share on $5.57 billion revenue, and the full-year consensus is $4.95 earnings per share on $18.3 billion revenue.
Factors that will strongly affect Teva's results for the fourth quarter of 2011 and first half of 2012 include a launch of a generic version of Pfizer Inc. (NYSE: PFE; LSE: PFZ) anti-cholesterol drug Lipitor.
Teva's share price has fallen 24% this year, although it has risen 6.5% in the past three months. The share price fell 1% in early trading on the TASE today to NIS 152.90, after rising 0.1% on Nasdaq yesterday to $40.90, giving a market cap of $36 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on December 14, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments